San Diego startup Iambic reported that physics‑informed algorithms combined with automated chemistry have shortened its chemistry‑to‑clinic timeline to roughly two years, according to a BioCentury profile. The company says integrated AI, synthesis automation, and high‑throughput characterization have begun delivering small molecules to early clinical testing and have attracted external partners. The profile details how model‑driven reaction planning and closed‑loop experimentation reduce design‑make‑test cycles that traditionally slow small‑molecule programs. For investors and pharma partners, the example signals faster preclinical pipelines and new options for outsourcing hit‑to‑lead and candidate optimization; the approach still requires validation across therapeutic modalities.